Evaluation of the geographical utility of Eastern Russell's viper (Daboia siamensis) antivenom from Thailand and an assessment of its protective effects against venom-induced nephrotoxicity.
Animals
Antivenins
/ pharmacology
Blood Coagulation Disorders
/ drug therapy
Blood Urea Nitrogen
China
Creatinine
/ blood
Kidney
/ pathology
Lethal Dose 50
Male
Myanmar
Rats
Rats, Sprague-Dawley
Renal Insufficiency
/ chemically induced
Daboia
Snake Bites
/ therapy
Taiwan
Thailand
Venoms
Viper Venoms
/ antagonists & inhibitors
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
23
03
2019
accepted:
18
09
2019
revised:
12
11
2019
pubmed:
24
10
2019
medline:
6
2
2020
entrez:
24
10
2019
Statut:
epublish
Résumé
Daboia siamensis (Eastern Russell's viper) is a medically important snake species found widely distributed across Southeast Asia. Envenomings by this species can result in systemic coagulopathy, local tissue injury and/or renal failure. While administration of specific antivenom is an effective treatment for Russell's viper envenomings, the availability of, and access to, geographically-appropriate antivenom remains problematic in many rural areas. In this study, we determined the binding and neutralizing capability of antivenoms manufactured by the Thai Red Cross in Thailand against D. siamensis venoms from four geographical locales: Myanmar, Taiwan, China and Thailand. The D. siamensis monovalent antivenom displayed extensive recognition and binding to proteins found in D. siamensis venom, irrespective of the geographical origin of those venoms. Similar immunological characteristics were observed with the Hemato Polyvalent antivenom, which also uses D. siamensis venom as an immunogen, but binding levels were dramatically reduced when using comparator monovalent antivenoms manufactured against different snake species. A similar pattern was observed when investigating neutralization of coagulopathy, with the procoagulant action of all four geographical venom variants neutralized by both the D. siamensis monovalent and the Hemato Polyvalent antivenoms, while the comparator monovalent antivenoms were ineffective. These in vitro findings translated into therapeutic efficacy in vivo, as the D. siamensis monovalent antivenom was found to effectively protect against the lethal effects of all four geographical venom variants preclinically. Assessments of in vivo nephrotoxicity revealed that D. siamensis venom (700 μg/kg) significantly increased plasma creatinine and blood urea nitrogen levels in anaesthetised rats. The intravenous administration of D. siamensis monovalent antivenom at three times higher than the recommended scaled therapeutic dose, prior to and 1 h after the injection of venom, resulted in reduced levels of markers of nephrotoxicity and prevented renal morphological changes, although lower doses had no therapeutic effect. This study highlights the potential broad geographical utility of the Thai D. siamensis monovalent antivenom for treating envenomings by the Eastern Russell's viper. However, only the early delivery of high antivenom doses appears to be capable of preventing venom-induced nephrotoxicity.
Sections du résumé
BACKGROUND
Daboia siamensis (Eastern Russell's viper) is a medically important snake species found widely distributed across Southeast Asia. Envenomings by this species can result in systemic coagulopathy, local tissue injury and/or renal failure. While administration of specific antivenom is an effective treatment for Russell's viper envenomings, the availability of, and access to, geographically-appropriate antivenom remains problematic in many rural areas. In this study, we determined the binding and neutralizing capability of antivenoms manufactured by the Thai Red Cross in Thailand against D. siamensis venoms from four geographical locales: Myanmar, Taiwan, China and Thailand.
METHODOLOGY/PRINCIPLE FINDINGS
The D. siamensis monovalent antivenom displayed extensive recognition and binding to proteins found in D. siamensis venom, irrespective of the geographical origin of those venoms. Similar immunological characteristics were observed with the Hemato Polyvalent antivenom, which also uses D. siamensis venom as an immunogen, but binding levels were dramatically reduced when using comparator monovalent antivenoms manufactured against different snake species. A similar pattern was observed when investigating neutralization of coagulopathy, with the procoagulant action of all four geographical venom variants neutralized by both the D. siamensis monovalent and the Hemato Polyvalent antivenoms, while the comparator monovalent antivenoms were ineffective. These in vitro findings translated into therapeutic efficacy in vivo, as the D. siamensis monovalent antivenom was found to effectively protect against the lethal effects of all four geographical venom variants preclinically. Assessments of in vivo nephrotoxicity revealed that D. siamensis venom (700 μg/kg) significantly increased plasma creatinine and blood urea nitrogen levels in anaesthetised rats. The intravenous administration of D. siamensis monovalent antivenom at three times higher than the recommended scaled therapeutic dose, prior to and 1 h after the injection of venom, resulted in reduced levels of markers of nephrotoxicity and prevented renal morphological changes, although lower doses had no therapeutic effect.
CONCLUSIONS/SIGNIFICANCE
This study highlights the potential broad geographical utility of the Thai D. siamensis monovalent antivenom for treating envenomings by the Eastern Russell's viper. However, only the early delivery of high antivenom doses appears to be capable of preventing venom-induced nephrotoxicity.
Identifiants
pubmed: 31644526
doi: 10.1371/journal.pntd.0007338
pii: PNTD-D-19-00470
pmc: PMC6850557
doi:
Substances chimiques
Antivenins
0
Venoms
0
Viper Venoms
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007338Subventions
Organisme : Medical Research Council
ID : MC_PC_15040
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17196
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200517/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17167
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L01839X/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Déclaration de conflit d'intérêts
Narongsak Chaiyabutr and Lawan Chanhome are currently employed by Queen Saovabha Memorial Institute, Thai Red Cross Society, where the antivenoms tested in this study was manufactured. The authors have no competing interests to declare.
Références
PLoS Negl Trop Dis. 2017 Oct 18;11(10):e0005969
pubmed: 29045429
J Proteomics. 2009 Mar 6;72(2):256-69
pubmed: 19457351
Toxicon. 2018 May;146:31-41
pubmed: 29567103
Commun Biol. 2018 Apr 19;1:34
pubmed: 30271920
Trans R Soc Trop Med Hyg. 2006 May;100(5):489-94
pubmed: 16325876
Toxicon. 2013 Jan;61:47-53
pubmed: 23142505
Toxicon. 2011 Sep 1;58(3):230-8
pubmed: 21704055
PLoS Negl Trop Dis. 2014 Oct 23;8(10):e3220
pubmed: 25340841
Toxicon. 2005 Jun 15;45(8):951-67
pubmed: 15922768
Biol Aujourdhui. 2010;204(1):87-91
pubmed: 20950580
PLoS Negl Trop Dis. 2009 Dec 22;3(12):e569
pubmed: 20027216
Curr Biol. 2016 Sep 26;26(18):2434-2445
pubmed: 27641771
Kidney Int. 1997 Jun;51(6):1956-69
pubmed: 9186889
Toxicon. 2012 Oct;60(5):943-53
pubmed: 22750531
Acta Trop. 2014 Apr;132:7-14
pubmed: 24384454
Clin Toxicol (Phila). 2014 Jul;52(6):604-10
pubmed: 24940643
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
Sci Rep. 2018 Jun 4;8(1):8545
pubmed: 29867131
PLoS Negl Trop Dis. 2010 Oct 26;4(10):e851
pubmed: 21049058
Kidney Int. 2005 Feb;67(2):659-67
pubmed: 15673314
Blood Coagul Fibrinolysis. 1995 Feb;6(1):65-72
pubmed: 7540879
Toxicon. 2003 Dec 15;42(8):827-40
pubmed: 15019485
Nat Rev Dis Primers. 2017 Oct 05;3:17079
pubmed: 28980622
Toxins (Basel). 2016 Mar 26;8(4):93
pubmed: 27023608
BMC Evol Biol. 2007 Jan 18;7:2
pubmed: 17233905
Toxicon. 2019 Oct;168:95-97
pubmed: 31254600
Pathology. 2006 Dec;38(6):568-72
pubmed: 17393987
Basic Clin Pharmacol Toxicol. 2015 Oct;117(4):274-9
pubmed: 25819552
Nephrology (Carlton). 2006 Oct;11(5):442-8
pubmed: 17014559
PLoS Negl Trop Dis. 2016 Dec 2;10(12):e0005172
pubmed: 27911900
Toxins (Basel). 2017 Sep 18;9(9):
pubmed: 28927001
J Venom Anim Toxins Incl Trop Dis. 2018 Mar 9;24:9
pubmed: 29556251
Toxicon. 2002 Sep;40(9):1291-8
pubmed: 12220714
Lancet. 1985 Dec 7;2(8467):1259-64
pubmed: 2866333
Toxins (Basel). 2017 Nov 25;9(12):
pubmed: 29186818
Toxins (Basel). 2014 Aug 19;6(8):2471-82
pubmed: 25153254
PLoS Negl Trop Dis. 2015 Aug 21;9(8):e0003968
pubmed: 26296235
Mol Biol Evol. 2011 Mar;28(3):1157-72
pubmed: 21062752
Neurotox Res. 2017 Jan;31(1):11-19
pubmed: 27401825